Athena Countouriotis
2021
In 2021, Athena Countouriotis earned a total compensation of $16.9M as President and Chief Executive Officer at Turning Point Therapeutics, a 11% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $507,546 |
|---|---|
| Option Awards | $9,779,254 |
| Salary | $650,700 |
| Stock Awards | $5,966,806 |
| Other | $36,552 |
| Total | $16,940,858 |
Countouriotis received $9.8M in option awards, accounting for 58% of the total pay in 2021.
Countouriotis also received $507.5K in non-equity incentive plan, $650.7K in salary, $6M in stock awards and $36.6K in other compensation.
Rankings
In 2021, Athena Countouriotis' compensation ranked 436th out of 12,415 executives tracked by ExecPay. In other words, Countouriotis earned more than 96.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 436 out of 12,415 | 97th |
Division Manufacturing | 138 out of 5,505 | 98th |
Major group Chemicals And Allied Products | 42 out of 2,375 | 98th |
Industry group Drugs | 37 out of 2,096 | 98th |
Industry Pharmaceutical Preparations | 22 out of 1,546 | 99th |
Source: SEC filing on April 29, 2022.
Countouriotis' colleagues
We found six more compensation records of executives who worked with Athena Countouriotis at Turning Point Therapeutics in 2021.
2021
Mohammad Hirmand
Turning Point Therapeutics
Chief Medical Officer
2021
Annette North
Turning Point Therapeutics
General Counsel
2021
Paolo Tombesi
Turning Point Therapeutics
Chief Financial Officer
2021
Siegfried PHD
Turning Point Therapeutics
Chief Scientific Officer
2021
Yi Larson
Turning Point Therapeutics
Chief Financial Officer
2021
Brian Baker
Turning Point Therapeutics